April 28, 2020 -- A new collaboration between Quotient Sciences and CytoAgents will accelerate the development of a lead COVID-19 drug candidate to human clinical trials, the companies announced.
The partnership will focus on rapid development of CytoAgents' lead COVID-19 drug candidate, GP1681, for phase I and II trials in 2020. The candidate is a small-molecule inhibitor of cytokine release in activated human immune cells that shows potential in blocking the "cytokine storms" associated with severe illness in COVID-19 cases.
Under the agreement, CytoAgents will use Quotient's formulation and manufacturing expertise to develop and rapidly supply drug product for clinical trials. Quotient will also work to develop a scalable solid oral dosage form for larger patient trials. The program will be conducted at Quotient's specialized drug handling and containment facility in Pennsylvania.